ARTICLE | Company News
Thromgen Inc. other research news
January 24, 2000 8:00 AM UTC
Thromgen received a $440,000 Phase II SBIR grant and a $100,000 Phase I STTR grant from the National Heart, Lung, and Blood Institute to develop thrombostatin as a treatment for acute coronary syndrom...